Effect of a biomimetic pathogen adsorbing device on inflammatory biomarkers in COVID‐19 patients
Jan Schmieszek, Thomas Fuehner, Isabelle Renger, Tobias Welte, Jan Menne, Jan Fuge, Maria P. van't Klooster, Andrea Paul, Alina Siegert, Dan‐Nicolae Borchina, Christine S. Falk, Jan T. KielsteinAbstract
Introduction
The Seraph 100 Microbind Affinity blood filter eliminate bacteria, viruses, fungi and toxins from blood stream.
Methods
This is a prospective multicenter observational biomarker trial in PCR‐positive SARS‐CoV‐2 patients with acute respiratory failure. Biomarkers were sequentially tested at three time points.
Results
Forty‐two patients with SARS‐CoV‐2 detected by PCR with acute respiratory failure were included. When receiving hemoperfusion treatment, 27 (64%) patients were on mechanical ventilation, 41 (98%) patients were treated in the ICU. The 3‐month survival was 52%. After one hemoperfusion treatment cycle, D‐dimer (p = 0.014), hemoglobin (p = 0.003) and LDH (p = 0.001) concentrations were significantly reduced 4 days after treatment. From the multiplex assay IL‐1b, CXCL8/ IL‐8, IL‐10, IL‐13, IL‐15, CCL11/Eotaxin, G‐CSF, and CXCL10/IP‐10 were significantly reduced 1 h after treatment, however not 4 days later.
Conclusion
Hemoperfusion with Seraph 100 Microbind Affinity Filter in patients with severe COVID‐19 can transiently reduce several inflammatory biomarkers in the blood.